Rapid point of care diagnostic tests for viral and bacterial respiratory tract infections-needs, advances, and future prospects

The Lancet Infectious Diseases

Volumn 14, Issue 11, 2014, Pages 1123-1135

  Zumla, Alimuddin ^a,b,i,k   Al Tawfiq, Jaffar A ^c   Enne, Virve I ^a   Kidd, Mike ^a,b   Drosten, Christian ^d   Breuer, Judy ^a,b   Muller, Marcel A ^d   Hui, David ^e   Maeurer, Markus ^f   Bates, Matthew ^a,k   Mwaba, Peter ^k   Al Hakeem, Rafaat ⁱ   Gray, Gregory ^g   Gautret, Philippe ^h   Al Rabeeah, Abdullah A ⁱ   Memish, Ziad A ^i,j   Gant, Vanya ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c DHAHRAN HEALTH CENTER   (Saudi Arabia)

^d UNIVERSITY OF BONN   (Germany)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f KAROLINSKA INSTITUTE   (Sweden)

^g UNIVERSITY OF FLORIDA   (United States)

^h AIX MARSEILLE UNIVERSITÉ   (France)

ⁱ MINISTRY OF HEALTH   (Saudi Arabia)

^j ALFAISAL UNIVERSITY   (Saudi Arabia)

^k UNIVERSITY TEACHING HOSPITAL   (Zambia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; NUCLEIC ACID; POLYADENYLATED RNA;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIGEN DETECTION; BACTERIAL INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DISEASE SURVEILLANCE; GENE AMPLIFICATION; GENOTYPE PHENOTYPE CORRELATION; HEALTH CARE SYSTEM; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; LOWER RESPIRATORY TRACT INFECTION; LUNG TUBERCULOSIS; MICROARRAY ANALYSIS; MICROBIAL COLONIZATION; MOLECULAR DIAGNOSIS; MULTIDRUG RESISTANCE; MULTIPLEX POLYMERASE CHAIN REACTION; NUCLEIC ACID AMPLIFICATION; PANDEMIC; POINT OF CARE TESTING; PUBLIC HEALTH; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT INFECTION; REVIEW; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; TURNAROUND TIME; VENTILATOR ASSOCIATED PNEUMONIA; VIRUS INFECTION; BACTERIAL INFECTIONS; HOSPITAL INFORMATION SYSTEM; MICROBIOLOGY; PROCEDURES; RESPIRATORY TRACT INFECTIONS; TRENDS; VIROLOGY; VIRUS DISEASES;

BACTERIAL INFECTIONS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; POINT-OF-CARE SYSTEMS; RESPIRATORY TRACT INFECTIONS; VIRUS DISEASES;

EID: 84908287355     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70827-8     Document Type: Review

References (140)

1. Dickson RP, Erb-Downward JR, Huffnagle GB Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis. Lancet Respiratory Med 2014, 2:238-246.
2. Bates M, Mudenda V, Mwaba P, Zumla A Deaths due to respiratory tract infections in Africa: a review of autopsy studies. Curr Opin Pulm Med 2013, 19:229-237.
3. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2224-2260.
4. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
5. Magiorakos AP, Suetens C, Monnet DL, et al. The rise of carbapenem resistance in Europe: just the tip of the iceberg?. Antimicrob Resist Infect Control 2013, 2:6.
6. Torres A, Peetermans WE, Viegi G, Blasi F Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 2013, 68:1057-1065.
7. Quartin AA, Scerpella EG, Puttagunta S, Kett DH A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study. BMC Infect Dis 2013, 13:561.
8. Pietersen E, Ignatius E, Streicher EM, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014, 383:1230-1239.
9. Sader HS, Farrell DJ, Flamm RK, Jones RN Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents 2014, 43:328-334.
10. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infectious Dis 2013, 13:785-796.
11. Godbole G, Gant V Respiratory tract infections in the immunocompromised. Curr Opin Pulm Med 2013, 19:244-250.
12. Kaltsas A, Sepkowitz K Community acquired respiratory and gastrointestinal viral infections: challenges in the immunocompromised host. Curr Opin Infect Dis 2012, 25:423-430.
13. Zumla A Current trends and newer concepts on diagnosis, management and prevention of respiratory tract infections. Curr Opin Pulm Med 2013, 19:189-191.
14. Wilke M, Grube RF, Bodmann KF Guideline-adherent initial intravenous antibiotic therapy for hospital-acquired/ventilator-associated pneumonia is clinically superior, saves lives and is cheaper than non guideline adherent therapy. Eur J Med Res 2011, 16:315-323.
15. Caliendo AM, Gilbert DN, Ginocchio CC, et al. Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis 2013, 57(suppl 3):S139-S170.
16. Chan JF, To KK, Tse H, Jin DY, Yuen KY Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol 2013, 21:544-555.
17. Yuen KY, Chan PK, Peiris M, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998, 351:467-471.
18. Middle East respiratory syndrome coronavirus (MERS-CoV) summary and literature update-as of Jan 20, 2014 2014, WHO, WHO, Geneva.
19. Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013, 13:529-539.
20. Le Page AK, Jager MM, Iwasenko JM, Scott GM, Alain S, Rawlinson WD Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients. Clin Infect Dis 2013, 56:1018-1029.
21. van der Linden JW, Camps SM, Kampinga GA, et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis 2013, 57:513-520.
22. Ji H, Gu Q, Chen LL, et al. Epidemiological and Clinical Characteristics and Risk Factors for Death of Patients with Avian Influenza A H7N9 Virus Infection from Jiangsu Province, Eastern China. PloS One 2014, 9:e89581.
23. Zhu H, Webby R, Lam TT, Smith DK, Peiris JS, Guan Y History of Swine influenza viruses in Asia. Curr Top Microbiol Immunol 2013, 370:57-68.
24. Huang G, Yu D, Zhu Z, et al. Outbreak of febrile respiratory illness associated with human adenovirus type 14p1 in Gansu Province, China. Influenza Other Respir Viruses 2013, 7:1048-1054.
25. Drysdale SB, Alcazar M, Wilson T, et al. Respiratory outcome of prematurely born infants following human rhinovirus A and C infections. Eur J Pediatr 2014, 173:913-919.
26. Mahony JB, Petrich A, Smieja M Molecular diagnosis of respiratory virus infections. Crit Rev Clin Lab Sci 2011, 48:217-249.
27. Tenover FC Developing molecular amplification methods for rapid diagnosis of respiratory tract infections caused by bacterial pathogens. Clin Infect Dis 2011, 52(suppl 4):S338-S345.
28. Alexander DJ, Brown IH Recent zoonoses caused by influenza A viruses. Rev Sci Tech 2000, 19:197-225.
29. Haagmans BL, Al Dhahiry SH, Reusken CB, et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis 2014, 14:140-145.
30. Van Reeth K Avian and swine influenza viruses: our current understanding of the zoonotic risk. Veterinary Res 2007, 38:243-260.
31. Khanna M, Fan J, Pehler-Harrington K, et al. The pneumoplex assays, a multiplex PCR-enzyme hybridization assay that allows simultaneous detection of five organisms, Mycoplasma pneumoniae, Chlamydia (Chlamydophila) pneumoniae, Legionella pneumophila, Legionella micdadei, and Bordetella pertussis, and its real-time counterpart. J Clin Microbiol 2005, 43:565-571.
32. Li J, Mao NY, Zhang C, et al. The development of a GeXP-based multiplex reverse transcription-PCR assay for simultaneous detection of 16 human respiratory virus types/subtypes. BMC InfectDis 2012, 12:189.
33. Reddington K, Tuite N, Barry T, O'Grady J, Zumla A Advances in multiparametric molecular diagnostics technologies for respiratory tract infections. Curr Opin Pulm Med 2013, 19:298-304.
34. Brittain-Long R, Andersson LM, Olofsson S, Lindh M, Westin J Seasonal variations of 15 respiratory agents illustrated by the application of a multiplex polymerase chain reaction assay. Scand J Infect Dis 2012, 44:9-17.
35. Walker HK, Hall WD, Hurst JW Clinical methods : the history, physical, and laboratory examinations. 3rd edN 1990, Butterworths, Boston.
36. Hastings TW, Boehm E A Study of Cultures from Sputum and Blood in Lobar Pneumonia. J Exp Med 1913, 17:239-251.
37. Le BM, Presti R The current state of viral diagnostics for respiratory infections. M Medicine 2009, 106:283-286.
38. Mahony JB Nucleic acid amplification-based diagnosis of respiratory virus infections. Expert Rev Anti Infect Ther 2010, 8:1273-1292.
39. Beck ET, Henrickson KJ Molecular diagnosis of respiratory viruses. Future Microbiol 2010, 5:901-916.
40. PJ G, RB TJ Review of rapid diagnostic tests for influenza. Clin Appl Immunol Rev 2004, 4:151-172.
41. Wu HS, Chiu SC, Tseng TC, et al. Serologic and molecular biologic methods for SARS-associated coronavirus infection, Taiwan. Emerg Infect Dis 2004, 10:304-310.
42. Anderson TP, Werno AM, Barratt K, Mahagamasekera P, Murdoch DR, Jennings LC Comparison of four multiplex PCR assays for the detection of viral pathogens in respiratory specimens. J Virol Methods 2013, 191:118-121.
43. Babady NE, Mead P, Stiles J, et al. Comparison of the Luminex xTAG RVP Fast assay and the Idaho Technology FilmArray RP assay for detection of respiratory viruses in pediatric patients at a cancer hospital. J Clin Microbiol 2012, 50:2282-2288.
44. Caliendo AM Multiplex PCR and emerging technologies for the detection of respiratory pathogens. Clin Infect Dis 2011, 52(suppl 4):S326-S330.
45. Hammond SP, Gagne LS, Stock SR, et al. Respiratory virus detection in immunocompromised patients with FilmArray respiratory panel compared to conventional methods. J Clin Microbiol 2012, 50:3216-3221.
46. Kim HK, Oh SH, Yun KA, Sung H, Kim MN Comparison of Anyplex II RV16 with the xTAG respiratory viral panel and Seeplex RV15 for detection of respiratory viruses. J Clin Microbiol 2013, 51:1137-1141.
47. Pierce VM, Hodinka RL Comparison of the GenMark Diagnostics eSensor respiratory viral panel to real-time PCR for detection of respiratory viruses in children. J Clin Microbiol 2012, 50:3458-3465.
48. Ryabinin VA, Kostina EV, Maksakova GA, Neverov AA, Chumakov KM, Sinyakov AN Universal oligonucleotide microarray for sub-typing of Influenza A virus. PloS One 2011, 6:e17529.
49. van der Vries E, Anber J, van der Linden A, et al. Molecular assays for quantitative and qualitative detection of influenza virus and oseltamivir resistance mutations. J Mol Diagn 2013, 15:347-354.
50. Selleri M, Piralla A, Rozera G, et al. Detection of haemagglutinin D222 polymorphisms in influenza A(H1N1)pdm09-infected patients by ultra-deep pyrosequencing. Clin Microbiol Infect 2013, 19:668-673.
51. Piralla A, Daleno C, Pariani E, et al. Virtual quantification of influenza A virus load by real-time RT-PCR. J Clin Virol 2013, 56:65-68.
52. Bennett NJ, Tabarani CM, Bartholoma NM, et al. Unrecognized viral respiratory tract infections in premature infants during their birth hospitalization: a prospective surveillance study in two neonatal intensive care units. J Pediatr 2012, 161:814-818.
53. Welti M, Jaton K, Altwegg M, Sahli R, Wenger A, Bille J Development of a multiplex real-time quantitative PCR assay to detect Chlamydia pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae in respiratory tract secretions. Diagn Microbiol Infect Dis 2003, 45:85-95.
54. Livermore DM, Wain J Revolutionising bacteriology to improve treatment outcomes and antibiotic stewardship. Infect Chemotherapy 2013, 45:1-10.
55. Peralta G, Sanchez MB, Garrido JC, et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother 2007, 60:855-863.
56. Annual Report of the Chief Medical Officer. Health 2011, SCD, UK Government, London, UK, (accessed July 4, 2014). https://www.gov.uk/government/publications/cmo-annual-report-2011-volume-one-on-the-state-of-the-public-s-health.
57. Tuite N, Reddington K, Barry T, Zumla A, Enne V Rapid nucleic acid diagnostics for the detection of antimicrobial resistance in Gram-negative bacteria: is it time for a paradigm shift?. J Antimicrob Chemother 2014, 69:1729-1733.
58. Bousbia S, Raoult D, La Scola B Pneumonia pathogen detection and microbial interactions in polymicrobial episodes. Future Microbiol 2013, 8:633-660.
59. Endimiani A, Hujer KM, Hujer AM, et al. Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia?. Clin infect dis 2011, 52(suppl 4):S373-S383.
60. Pulido MR, Garcia-Quintanilla M, Martin-Pena R, Cisneros JM, McConnell MJ Progress on the development of rapid methods for antimicrobial susceptibility testing. J Antimicrob Chemother 2013, 68:2710-2717.
61. Dubouix-Bourandy A, de Ladoucette A, Pietri V, et al. Direct detection of Staphylococcus osteoarticular infections by use of Xpert MRSA/SA SSTI real-time PCR. J Clin Microbiol 2011, 49:4225-4230.
62. Curetis. Curetis UNYVERO Pneumonia application guide. In: Curetis, ed; 2014.
63. Biofire. FilmArray Respiratory Panel. In: Biomereiux B, editor. online: Biofire; 2014.
64. Poritz MA, Blaschke AJ, Byington CL, et al. FilmArray, an automated nested multiplex PCR system for multi-pathogen detection: development and application to respiratory tract infection. PloS One 2011, 6:e26047.
65. Bartlett JG Diagnostic tests for agents of community-acquired pneumonia. ClinInfect Dis 2011, 52(suppl 4):S296-S304.
66. Cercenado E, Marin M, Burillo A, Martin-Rabadan P, Rivera M, Bouza E Rapid detection of Staphylococcus aureus in lower respiratory tract secretions from patients with suspected ventilator-associated pneumonia: evaluation of the Cepheid Xpert MRSA/SA SSTI assay. J Clin Microbiol 2012, 50:4095-4097.
67. Berton DC, Kalil AC, Teixeira PJ Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. Cochrane Database Syst Rev 2012, 1. CD006482.
68. Babady NE The FilmArray(R) respiratory panel: an automated, broadly multiplexed molecular test for the rapid and accurate detection of respiratory pathogens. Expert Rev Mol Diagn 2013, 13:779-788.
69. Bertelli C, Greub G Rapid bacterial genome sequencing: methods and applications in clinical microbiology. Clin Microbiol Infect 2013, 19:803-813.
70. Snitkin ES, Zelazny AM, Thomas PJ, et al. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med 2012, 4:148ra116.
71. Daber R, Sukhadia S, Morrissette JJ Understanding the limitations of next generation sequencing informatics, an approach to clinical pipeline validation using artificial data sets. Cancer Genetics 2013, 206:441-448.
72. Biesecker LG, Burke W, Kohane I, Plon SE, Zimmern R Next-generation sequencing in the clinic: are we ready?. Nat Rev Genet 2012, 13:818-824.
73. Sanger sequencing DNA worklow Lifetechnologies, (accessed April 22, 2014). http://www.lifetechnologies.com/uk/en/home/life-science/sequencing/sanger-sequencing/sanger-dna-sequencing.html.
74. Tu J, Ge Q, Wang S, Wang L, et al. Pair-barcode high-throughput sequencing for large-scale multiplexed sample analysis. BMC Genomics 2012, 13:43.
75. PATHSEEK, (acessed July 1, 2014). http://www.ucl.ac.uk/pathseek.
76. Dolled-Filhart MP1, Lee M, Ou-Yang CW, Haraksingh RR, Lin JC Computational and bioinformatics frameworks for next-generation whole exome and genome sequencing. Scientific World Journal 2013, 2013:730210.
77. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013, 13:752-761.
78. Assiri A, McGeer A, Perl TM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013, 369:407-416.
79. Cotten M, Watson SJ, Kellam P, et al. Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study. Lancet 2013, 382:1993-2002.
80. Cotten M, Watson SJ, Zumla AI, et al. Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus. MBio 2014, 5:e01062. e01013.
81. Memish ZA, Al-Tawfiq JA, Makhdoom HQ, et al. Screening for Middle East respiratory syndrome coronavirus infection in hospital patients and their healthcare worker and family contacts: a prospective descriptive study. Clin Microbiol Infect 2014, 20:469-474.
82. Abd El Wahed A, Patel P, Heidenreich D, Hufert FT, Weidmann M Reverse transcription recombinase polymerase amplification assay for the detection of middle East respiratory syndrome coronavirus. PLoS Curr 2013, 5:e2e8364.
83. Corman VM, Eckerle I, Bleicker T, et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill 2012, 17:1-6.
84. Corman V, Muller M, Costabel U, et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill 2012, 17:1-9.
85. Ithete NL, Stoffberg S, Corman VM, et al. Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa. Emerg Infect Dis 2013, 19:1697-1699.
86. Memish ZA, Mishra N, Olival KJ, et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect dis 2013, 19:1819-1823.
87. Anthony SJ, Ojeda-Flores R, Rico-Chavez O, et al. Coronaviruses in bats from Mexico. J Gen Virol 2013, 94:1028-1038.
88. Alagaili AN, Briese T, Mishra N, et al. Middle East respiratory syndrome coronavirus infection in dromedary camels in saudi arabia. MBio 2014, 5:e00884. e00814.
89. Buchholz U, Muller MA, Nitsche A Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012. Euro Surveill 2013, 18:1-7.
90. Aburizaiza AS, Mattes FM, Azhar EI, et al. Investigation of anti-middle East respiratory syndrome antibodies in blood donors and slaughterhouse workers in Jeddah and Makkah, Saudi Arabia, fall 2012. J Infect Dis 2014, 209:243-246.
91. Chan KH, Chan JF, Tse H, et al. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect 2013, 67:130-140.
92. Drosten C, Seilmaier M, Corman VM, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 2013, 13:745-751.
93. Payne DC, Iblan I, Alqasrawi S, et al. Stillbirth During Infection With Middle East Respiratory Syndrome Coronavirus. J Infect 2014, 209:1870-1872.
94. Corman VM, Kallies R, Philipps H, et al. Characterization of a novel betacoronavirus related to middle East respiratory syndrome coronavirus in European hedgehogs. J Virol 2014, 88:717-724.
95. Hemida MG, Perera RA, Wang P, et al. Middle East Respiratory Syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. Euro surveill 2013, 18:20659.
96. Meyer B, Muller MA, Corman VM, et al. Antibodies against MERS Coronavirus in Dromedary Camels, United Arab Emirates, 2003 and 2013. Emerging Infectious Diseases 2014, 20:552-559.
97. Reusken CB, Haagmans BL, Muller MA, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 2013, 13:859-866.
98. Memish ZA, Cotten M, Meyer B Human Infection with MERS Coronavirus after exposure to infected camels, Saudi Arabia, 2013. Emerg Infect Dis 2014, 20:1012-1015.
99. Agnihothram S, Gopal R, Yount BL, et al. Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J Infect Dis 2014, 209:995-1006.
100. Gierer S, Hofmann-Winkler H, Albuali WH, et al. Lack of MERS coronavirus neutralizing antibodies in humans, eastern province, Saudi Arabia. Emerg Infect Dis 2013, 19:2034-2036.
101. Perera RA, Wang P, Gomaa MR, et al. Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill 2013, 18:20574.
102. Corman VM, Jores J, Meyer B, et al. Antibodies against MERS Coronavirus in Dromedary Camels, Kenya, 1992-2013. Emerg Infect Dis 2014, published online Aug. 10.3201/eid2008.140596.
103. Reusken CB, Ababneh M, Raj VS, et al. Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveill 2013, 18:20662.
104. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013, 495:251-254.
105. Reusken C, Mou H, Godeke GJ, et al. Specific serology for emerging human coronaviruses by protein microarray. Euro Surveill 2013, 18:20441.
106. Azhar EI, El-Kafrawy SA, Farraj SA, et al. Evidence for Camel-to-Human Transmission of MERS Coronavirus. N Engl J Med 2014, 370:2499-2505.
107. Global tuberculosis report 2013 (in IRIS) 2013, WHO, World Health Organization, Geneva, (accessed July 1, 2014). http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf?ua=1.
108. McNerney R, Maeurer M, Abubakar I, et al. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis 2012, 205(suppl 2):S147-S158.
109. TruDiagnosis Today Akonni, (accessed April 7, 2014). http://www.akonni.com/trudiagnosis/trudiagnosis-today.html.
110. Technologies ND Home Page (accessed July 4, 2014). http://www.ndtechnology.co.uk/cms/.
111. Alere. Alere to develop simple, affordable point-of-care nucleic acid test for tuberculosis and expand manufacturing for POC HIV Vviral load platform. In: Alere, editor. online: Alere; 2014.
112. Mulvey MC, Sacksteder KA, Einck L, Nacy CA Generation of a novel nucleic acid-based reporter system to detect phenotypic susceptibility to antibiotics in Mycobacterium tuberculosis. MBio 2012, 3:e00312. e00311.
113. Castan P, de Pablo A, Fernandez-Romero N, et al. Point-of-care system for detection of Mycobacterium tuberculosis and rifampin resistance in sputum samples. J Clin Microbiol 2014, 52:502-507.
114. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014, 1. CD009593.
115. Autogenomics (accessed Apr 7, 2014). http://www.autogenomics.com/?q=node/178.
116. Cepheid (accessed April 7, 2014). http://www.cepheid.com/us/healthcare-impact/emagazine/item/53-the-need-for-better-diagnostic-tests-for-pediatric-tuberculosis.
117. Bi A, Nakajima C, Fukushima Y, et al. A rapid loop-mediated isothermal amplification assay targeting hspX for the detection of Mycobacterium tuberculosis complex. Jpn J Infect Dis 2012, 65:247-251.
118. Barnard M, Gey van Pittius NC, van Helden PD, Bosman M, Coetzee G, Warren RM The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay. J Clin Microbiol 2012, 50:3712-3716.
119. Icubate (accessed July 15, 2014). http://icubate.com/index.php/product/myco/.
120. Liu J, Yue J, Yan Z, et al. Performance assessment of the CapitalBio mycobacterium identification array system for identification of mycobacteria. J Clin Microbiol 2012, 50:76-80.
121. Nikam C, Jagannath M, Narayanan MM, et al. Rapid diagnosis of Mycobacterium tuberculosis with Truenat MTB: a near-care approach. PloS One 2013, 8:e51121.
122. Lawn SD, Kerkhoff AD, Vogt M, Wood R Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 2012, 12:201-209.
123. Diagnostics G (accessed April 7, 2014). http://www.globalbiodiagnostics.com/.
124. Nanologix (accessed April 7, 2014). http://nanologix.com/.
125. Toit K, Mitchell S, Balabanova Y, et al. The Colour Test for drug susceptibility testing of Mycobacterium tuberculosis strains. Int J Tuberc Lung Dis 2012, 16:1113-1118.
126. Hall L, Jude KP, Clark SL, et al. Evaluation of the Sensititre MycoTB plate for susceptibility testing of the Mycobacterium tuberculosis complex against first- and second-line agents. J Clin Microbiol 2012, 50:3732-3734.
127. Phillips M, Basa-Dalay V, Blais J, et al. Point-of-care breath test for biomarkers of active pulmonary tuberculosis. Tuberculosis 2012, 92:314-320.
128. Rice JE, Reis AH, Rice LM, Carver-Brown RK, Wangh LJ Fluorescent signatures for variable DNA sequences. Nucleic Acids Res 2012, 40:e164.
129. Lewis JJ, Chihota VN, van der Meulen M, et al. Proof-of-concept evaluation of an automated sputum smear microscopy system for tuberculosis diagnosis. PloS One 2012, 7:e50173.
130. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010, 48:229-237.
131. Osman M, Simpson JA, Caldwell J, Bosman M, Nicol MP GeneXpert MTB/RIF version G4 for identification of rifampin-resistant tuberculosis in a programmatic setting. J Clin Microbiol 2014, 52:635-637.
132. Scott LE, McCarthy K, Gous N, et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 2011, 8:e1001061.
133. Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 2014, 383:424-435.
134. Williamson DA, Basu I, Bower J, Freeman JT, Henderson G, Roberts SA An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis. Diagn Microbiol Infect Dis 2012, 74:207-209.
135. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system : policy statement 2011, WHO, World Health Organization, Geneva, (accessed July 1, 2014). http://apps.who.int/iris/bitstream/10665/112472/1/9789241506335_eng.pdf?ua=1.
136. Lawn SD, Mwaba P, Bates M, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013, 13:349-361.
137. Tissari P, Zumla A, Tarkka E, et al. Accurate and rapid identification of bacterial species from positive blood cultures with a DNA-based microarray platform: an observational study. Lancet 2010, 375:224-230.
138. Xu M, Qin X, Astion ML, et al. Implementation of filmarray respiratory viral panel in a core laboratory improves testing turnaround time and patient care. Am J Clin Pathol 2013, 139:118-123.
139. RID-RTI project (EU,FP7, Rapid Identification of Respiratory tract Infections) (accessed April 7, 2014). http://www.life-sciences-europe.com/organisation/rid-rti-project-fp7-rapid-identification-respiratory-tract-2001-32045.html.
140. RAPP-ID (accessed April 7, 2014). http://www.ua.ac.be/main.aspx?c=RAPP-ID&n=93947.